≡

Recombinant Retinoschisin (RS)

RS1; XLRS1; Retinoschisis X-Linked,Juvenile 1; X-linked juvenile retinoschisis protein

  • Product No.RPJ847Mu01
  • Organism SpeciesMus musculus (Mouse) Same name, Different species.
  • SourceProkaryotic expression
  • HostE.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationMembrane, Secreted
  • Predicted Molecular Mass26.7kDa
  • Accurate Molecular Mass27kDa(Analysis of differences refer to the manual)
  • Residues & TagsSer24-Ala224 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder
  • Purity> 95%
  • Isoelectric Point5.3
  • Applications Positive Control; Immunogen; SDS-PAGE; WB.
    If bio-activity of the protein is needed, please check active protein.
  • DownloadInstruction Manual
  • UOM 10µg50µg 200µg 1mg 5mg
  • FOB US$   US$   US$   US$   US$  
    For more details, please contact local distributors!

SEQUENCE

USAGE

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Hum Gene Ther Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. PubMed: 22295905
IEEE Transactions on Magnetics Influence of Iron Oxide Nanoparticles on Innate and Genetically Modified Secretion Profiles of Mesenchymal Stem Cells Scholarsportal: Source
International Journal of Pharmaceutics A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases Pubmed:24576595
22 Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles Pubmed:26986855
UBC Library Cell based therapeutics for retinal degenerations cIRcle:1.0303136
Molecular Vision An ex vivo gene therapy approach in X-linked retinoschisis pubmed:27390514
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPJ847Mu01 Recombinant Retinoschisin (RS) Positive Control; Immunogen; SDS-PAGE; WB.